Tag: big pharma

DOD Awards $104 Million for Procurement of Syringes in Support of U.S. COVID-19 Vaccination Campaign

On August 4, the Department of Defense’s (DOD) Joint Acquisition Task Force (JATF), in support of the Department of Health and Human Services’ (HHS) Strategic National Stockpile (SNS), awarded $104 million in contracts to procure syringes and safety needles, enabling the nationwide administration of a U.S. Food and Drug Administration (FDA)-approved COVID-19 vaccine, once one is available. The syringes and safety needles are critical to the nation’s COVID-19 vaccination strategy, providing a total of 500 million safety syringes over a 12-month period, with more than 134 million of the total number delivered by the end of 2020.

The syringes and safety needles will be placed into the SNS so they will be readily available to quickly and efficiently vaccinate the U.S. population once a safe and efficacious COVID-19 vaccine is developed. This procurement is the latest in a series of recent contracts highlighting a collaborative “whole-of-government” approach in response to the COVID-19 threat.

The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) partnered with HHS and the Army Contracting Command – Aberdeen Proving Ground (ACC-APG), to select and award contracts to six companies: Duopross Meditech Corporation ($48 million), Cardinal Health Inc. ($15 million), Gold Coast Medical Supply, LP ($14 million), HTL STREFA Inc. ($12 million), Quality Impact, Inc. ($9 million), and Medline Industries, Inc. ($6 million). The companies represent a mix of large and small medical product manufacturers and distributors.

Keep reading

The Public Health Legacy of the 1976 Swine Flu Outbreak

The Swine Flu Program was marred by a series of logistical problems ranging from the production of the wrong vaccine strain to a confrontation over liability protection to a temporal connection of the vaccine and a cluster of deaths among an elderly population in Pittsburgh. The most damning charge against the vaccination program was that the shots were correlated with an increase in the number of patients diagnosed with an obscure neurological disease known as Guillain–Barré syndrome (1).

Keep reading

Red Flags Soar As Big Pharma Will Be Exempt From COVID-19 Vaccine Liability Claims

Last week we warned readers to be cautious about new COVID-19 vaccines, highlighting how key parts of the clinical trials are being skipped as big pharma will not be held accountable for adverse side effects for administering the experimental drugs.

A senior executive from AstraZeneca, Britain’s second-largest drugmaker, told Reuters that his company was just granted protection from all legal action if the company’s vaccine led to damaging side effects.

Keep reading